Eating on GLP-1 without counting: a calmer way.

1. Why calorie counting is the wrong tool on AOMs

Calorie counting was designed for an environment where the main behavioural problem was eating more than the body needs. That is not the situation on an anti-obesity medication. The medication itself reduces hunger and slows gastric emptying. In a dedicated semaglutide 2.4 mg ad libitum substudy (Friedrichsen et al., 2021), participants showed a roughly 35% reduction in energy intake versus placebo, beginning in the first weeks of treatment, well before dose escalation was complete.⁵ Sustained weight loss in the parent STEP-1 trial of weekly semaglutide 2.4 mg followed.¹ Many adults on a maintenance dose of semaglutide or tirzepatide spontaneously eat substantially less than they did before, often in the 1,200 to 1,800 kcal range, with day-to-day variation. Some days are lower than that, especially the first 24 to 48 hours after the injection.

In this context, asking the patient to count what they eat usually achieves three things at once: it adds an unnecessary cognitive load on a brain that is already adjusting; it amplifies the focus on numbers rather than on satiety signals that the medication is actively reshaping; and it raises the risk of disordered eating, especially in adults with a history of restriction-binge cycles. Major obesity guidelines (Endocrine Society 2015, NICE NG246) recommend pairing AOMs with a comprehensive lifestyle intervention. The clinical concern about layering a fad or nutritionally unbalanced restrictive diet on top of pharmacotherapy is widely shared (NICE NG246 §1.16.7).⁴

2. What the body is doing under the hood

GLP-1 receptor agonists (semaglutide, liraglutide) and dual GLP-1/GIP agonists (tirzepatide) act on satiety circuits in the brainstem and hypothalamus, and slow gastric emptying. The result is twofold: meals feel larger than they used to, and the signal that you are full arrives earlier. This is the same mechanism that explains most gastrointestinal side effects.³ It is also why the food strategy that worked for you before the medication is rarely the right one now. The body is sending different signals; the eating pattern needs to follow.

3. Five things to focus on instead

None of what follows requires a kitchen scale or a tracker. The whole point is that the medication does the calorie work; you do the structure work.

4. Rhythm: three meals and one small snack

The most reliable structure on a GLP-1 medication is the simplest one. Three meals at predictable times, plus one small snack if your day is long, with each meal small enough that you finish without forcing it. Predictable timing matters because gastric emptying is slow; eating an unplanned second lunch on top of a still-half-full stomach is what produces reflux, fullness pain, and the "I cannot eat anymore today" feeling that often leads to skipped dinners and protein deficits.

If your appetite is very low on a given day, smaller meals more often (five small ones) are more comfortable than three normal-sized ones. The total intake is not what is most important on those days; the protein floor is.

5. Protein at every meal: 1.2 to 1.6 g/kg/day

On an anti-obesity medication, between 25% and 40% of the weight you lose is lean tissue, including muscle (around 25% in the SURMOUNT-1 body-composition substudy on tirzepatide; closer to 35-40% in the STEP-1 DXA substudy on semaglutide). Protecting that muscle is the single most useful thing nutrition can do during weight loss, and it is also the most under-discussed. Phillips and colleagues, summarising the evidence on protein needs beyond the RDA, recommend 1.2 to 1.6 g/(kg·day) of high-quality protein for adults pursuing health, satiety, or weight management goals.² For a 90 kg adult, that is roughly 110 to 145 g of protein per day, distributed across meals (around 30 to 40 g per meal). The French GCC-CSO/FORCE 2026 position paper sets a minimum protein floor of 60 g/day under AOM and recommends increasing intake further in patients at risk of muscle loss, with a nutrition professional.

What this looks like in practice:

• Breakfast: two eggs and Greek yoghurt, or a protein-forward smoothie with milk and a scoop of whey or pea protein, or cottage cheese on rye bread.
• Lunch: a palm-sized portion of fish, chicken, tofu, lentils, or beef, with vegetables and a starch you tolerate.
• Dinner: the same logic, lighter if your stomach is sensitive in the evening.
• Snack: Greek yoghurt, edamame, a handful of almonds, a protein bar that does not upset your stomach, or a slice of cheese.

Protein is also the macronutrient with the strongest satiety signal. On a stomach that is already easily full, that signal works in your favour: a protein-forward meal feels comfortable for hours. A carbohydrate-forward meal often does not. Pair protein with resistance training to translate the intake into muscle: see our piece on muscle, bone and GLP-1.

6. Fibre and hydration, not optional

Slow gastric emptying plus reduced intake equals constipation for a meaningful share of patients. Fibre and water are not "wellness" suggestions on a GLP-1; they are part of the tolerability strategy. Aim for 25 to 30 g of fibre per day from real food (vegetables, fruit, legumes, oats, whole grains, nuts, seeds), spread across meals so the gut is never overloaded at once. Aim for 1.5 to 2 L of water per day, more on injection days and in hot weather. Many of the headaches and fatigue people attribute to the medication are, in fact, mild dehydration.

If constipation is a recurring problem despite fibre and water, talk to your prescribing physician before reaching for stimulant laxatives. Magnesium oxide, kiwi fruit, or psyllium are often a kinder first step. The 2023 retrospective cohort study of GLP-1 GI events (Sodhi et al., PharMetrics Plus claims database) identified bowel obstruction as a rare but real signal; persistent constipation that does not respond to first-line measures is a reason to consult, not to push through.³

7. Satiety signals: relearning what "full" means

The most useful skill on a GLP-1 medication is also the most subtle: paying attention to early satiety. Stop eating when you are comfortable, not full in the old sense. The pre-medication signal of "I should keep going because there is still room" no longer maps onto the new physiology. The signal of "I feel a slight pressure in the upper stomach" is your new "full". Pushing past it produces nausea, reflux, and very often the post-injection sulfur burps that nobody wants. Leftovers are not a moral failure on this medication; they are the new default.

8. Appetite-flat days: how to handle them

Some days, often the 24 to 48 hours after an injection or after a dose escalation, food simply does not appeal. The risk on those days is dehydration and a protein deficit, not under-eating in calories. Keep a short list of "rescue" foods that you can eat when nothing else feels possible:

• Protein in fluid form: Greek yoghurt drinks, kefir, milk, a whey or pea protein shake, miso soup with tofu.
• Plain, low-fat, low-fragrance foods: rice, plain crackers, banana, cooked carrot.
• Cool foods: often easier on a queasy stomach than warm ones.
• Frequent small sips of water rather than large glasses.

If you cannot keep fluids down for more than 24 hours, that is no longer an appetite-flat day; that is a reason to call your physician. See our piece on GLP-1 side effects, month by month for the red flags.

9. The no-fad-diet principle

People often arrive on an AOM with a long history of restrictive diets. The temptation to layer one more (keto, low-carb, intermittent fasting taken to an extreme) on top of a medication that is already cutting intake by several hundred calories a day is real. The risk is also real: muscle loss, fatigue, micronutrient deficiencies, mood drops, gallstones, and a sharply higher chance of disordered eating. Major obesity guidelines (Endocrine Society 2015, NICE NG246, GCC-CSO/FORCE 2026) recommend that AOMs be used alongside a comprehensive lifestyle intervention that includes a moderate, sustainable energy deficit, rather than a fad or nutritionally unbalanced restrictive diet (NICE NG246 §1.16.7; §1.17.2).⁴ On a GLP-1 medication, that energy deficit is often produced spontaneously by the medication's effect on appetite, so most patients do not need to add formal calorie counting on top.

What that looks like for most people is closer to a Mediterranean pattern (vegetables, legumes, whole grains, fish, olive oil, fermented dairy, fruit, herbs, modest amounts of meat) adjusted for your tolerance, your culture, and your appetite, with attention to protein and fibre at every meal. The structure protects the medication; it does not replace it.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
2. Phillips SM, Chevalier S, Leidy HJ. Protein "requirements" beyond the RDA: implications for optimizing health. Applied Physiology, Nutrition, and Metabolism 2016;41(5):565-572. doi:10.1139/apnm-2015-0550. PMID 26960445.
3. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA 2023;330(18):1795-1797. doi:10.1001/jama.2023.19574. PMID 37796527.
4. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2015;100(2):342-362. doi:10.1210/jc.2014-3415. PMID 25590212. NICE. Overweight and obesity management. NICE guideline NG246. London: NICE, 2025. www.nice.org.uk/guidance/ng246.
5. Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism 2021;23(3):754-762. doi:10.1111/dom.14280. PMID 33269532.